JPWO2019157138A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019157138A5 JPWO2019157138A5 JP2020542562A JP2020542562A JPWO2019157138A5 JP WO2019157138 A5 JPWO2019157138 A5 JP WO2019157138A5 JP 2020542562 A JP2020542562 A JP 2020542562A JP 2020542562 A JP2020542562 A JP 2020542562A JP WO2019157138 A5 JPWO2019157138 A5 JP WO2019157138A5
- Authority
- JP
- Japan
- Prior art keywords
- liposome
- group
- pemetrexed
- glutamil
- oxidized
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002502 liposome Substances 0.000 claims 30
- QOFFJEBXNKRSPX-ZDUSSCGKSA-N pemetrexed Chemical compound C1=N[C]2NC(N)=NC(=O)C2=C1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QOFFJEBXNKRSPX-ZDUSSCGKSA-N 0.000 claims 23
- 229960005079 pemetrexed Drugs 0.000 claims 23
- 239000000203 mixture Substances 0.000 claims 19
- 229920001223 polyethylene glycol Polymers 0.000 claims 11
- 230000008685 targeting Effects 0.000 claims 9
- 108010040003 polyglutamine Proteins 0.000 claims 8
- 229920000155 polyglutamine Polymers 0.000 claims 8
- 239000002202 Polyethylene glycol Substances 0.000 claims 7
- 238000000034 method Methods 0.000 claims 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 4
- 102000010449 Folate receptor beta Human genes 0.000 claims 4
- 108050001930 Folate receptor beta Proteins 0.000 claims 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 4
- 239000000839 emulsion Substances 0.000 claims 4
- 102000006815 folate receptor Human genes 0.000 claims 4
- 108020005243 folate receptor Proteins 0.000 claims 4
- -1 2-hydroxypropyl Chemical group 0.000 claims 3
- 229920002498 Beta-glucan Polymers 0.000 claims 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 3
- 239000000427 antigen Substances 0.000 claims 3
- 102000036639 antigens Human genes 0.000 claims 3
- 108091007433 antigens Proteins 0.000 claims 3
- 238000001125 extrusion Methods 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims 2
- LVNGJLRDBYCPGB-LDLOPFEMSA-N (R)-1,2-distearoylphosphatidylethanolamine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[NH3+])OC(=O)CCCCCCCCCCCCCCCCC LVNGJLRDBYCPGB-LDLOPFEMSA-N 0.000 claims 2
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 claims 2
- 238000010146 3D printing Methods 0.000 claims 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 2
- 102000010451 Folate receptor alpha Human genes 0.000 claims 2
- 108050001931 Folate receptor alpha Proteins 0.000 claims 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 2
- 101001105486 Homo sapiens Proteasome subunit alpha type-7 Proteins 0.000 claims 2
- 229930195725 Mannitol Natural products 0.000 claims 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 108010020346 Polyglutamic Acid Proteins 0.000 claims 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims 2
- 102100021201 Proteasome subunit alpha type-7 Human genes 0.000 claims 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 2
- 102100023119 Sperm-egg fusion protein Juno Human genes 0.000 claims 2
- 101710093389 Sperm-egg fusion protein Juno Proteins 0.000 claims 2
- 102000002689 Toll-like receptor Human genes 0.000 claims 2
- 108020000411 Toll-like receptor Proteins 0.000 claims 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims 2
- 125000000129 anionic group Chemical group 0.000 claims 2
- 210000004899 c-terminal region Anatomy 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 235000012000 cholesterol Nutrition 0.000 claims 2
- 239000008121 dextrose Substances 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 238000005516 engineering process Methods 0.000 claims 2
- BPSMYQFMCXXNPC-MFCPCZTFSA-N eritoran Chemical class O[C@H]1[C@H](OCCCCCCCCCC)[C@@H](NC(=O)CC(=O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O[C@@H]1CO[C@H]1[C@H](NC(=O)CCCCCCCCC\C=C/CCCCCC)[C@@H](OCC[C@@H](CCCCCCC)OC)[C@H](OP(O)(O)=O)[C@@H](COC)O1 BPSMYQFMCXXNPC-MFCPCZTFSA-N 0.000 claims 2
- 238000001704 evaporation Methods 0.000 claims 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 claims 2
- 230000036571 hydration Effects 0.000 claims 2
- 238000006703 hydration reaction Methods 0.000 claims 2
- 229960001438 immunostimulant agent Drugs 0.000 claims 2
- 239000003022 immunostimulating agent Substances 0.000 claims 2
- 230000003308 immunostimulating effect Effects 0.000 claims 2
- 238000002347 injection Methods 0.000 claims 2
- 239000007924 injection Substances 0.000 claims 2
- 239000000594 mannitol Substances 0.000 claims 2
- 235000010355 mannitol Nutrition 0.000 claims 2
- 239000003550 marker Substances 0.000 claims 2
- 239000012528 membrane Substances 0.000 claims 2
- 230000007935 neutral effect Effects 0.000 claims 2
- 229920000729 poly(L-lysine) polymer Polymers 0.000 claims 2
- 229920002401 polyacrylamide Polymers 0.000 claims 2
- 239000000243 solution Substances 0.000 claims 2
- 238000003756 stirring Methods 0.000 claims 2
- 239000010409 thin film Substances 0.000 claims 2
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 claims 1
- CDZVJFRXJAUXPP-AREMUKBSSA-N 2-O-glutaroyl-1-O-palmitoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCC(O)=O)COP([O-])(=O)OCC[N+](C)(C)C CDZVJFRXJAUXPP-AREMUKBSSA-N 0.000 claims 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 208000035473 Communicable disease Diseases 0.000 claims 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims 1
- OVBPIULPVIDEAO-LBPRGKRZSA-N Folic acid Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims 1
- 239000007995 HEPES buffer Substances 0.000 claims 1
- 150000008575 L-amino acids Chemical class 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 claims 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims 1
- 239000004372 Polyvinyl alcohol Substances 0.000 claims 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 229930006000 Sucrose Natural products 0.000 claims 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 229920006187 aquazol Polymers 0.000 claims 1
- 239000012861 aquazol Substances 0.000 claims 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims 1
- VSGNNIFQASZAOI-UHFFFAOYSA-L calcium acetate Chemical compound [Ca+2].CC([O-])=O.CC([O-])=O VSGNNIFQASZAOI-UHFFFAOYSA-L 0.000 claims 1
- 239000001639 calcium acetate Substances 0.000 claims 1
- 229960005147 calcium acetate Drugs 0.000 claims 1
- 235000011092 calcium acetate Nutrition 0.000 claims 1
- 190000008236 carboplatin Chemical compound 0.000 claims 1
- 229960004562 carboplatin Drugs 0.000 claims 1
- 125000002091 cationic group Chemical group 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 229920001577 copolymer Polymers 0.000 claims 1
- 239000002577 cryoprotective agent Substances 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 238000010494 dissociation reaction Methods 0.000 claims 1
- 230000005593 dissociations Effects 0.000 claims 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 claims 1
- 229960000304 folic acid Drugs 0.000 claims 1
- 235000019152 folic acid Nutrition 0.000 claims 1
- 239000011724 folic acid Substances 0.000 claims 1
- 125000003929 folic acid group Chemical group 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 229920000370 gamma-poly(glutamate) polymer Polymers 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 210000000987 immune system Anatomy 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 125000005439 maleimidyl group Chemical group C1(C=CC(N1*)=O)=O 0.000 claims 1
- FQPSGWSUVKBHSU-UHFFFAOYSA-N methacrylamide Chemical compound CC(=C)C(N)=O FQPSGWSUVKBHSU-UHFFFAOYSA-N 0.000 claims 1
- 108010071584 oxidized low density lipoprotein Proteins 0.000 claims 1
- 229960002621 pembrolizumab Drugs 0.000 claims 1
- 125000001095 phosphatidyl group Chemical group 0.000 claims 1
- 229920000773 poly(2-methyl-2-oxazoline) polymer Polymers 0.000 claims 1
- 229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 claims 1
- 229920002643 polyglutamic acid Polymers 0.000 claims 1
- 229920000223 polyglycerol Polymers 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 229920001451 polypropylene glycol Polymers 0.000 claims 1
- 229920002451 polyvinyl alcohol Polymers 0.000 claims 1
- 239000001103 potassium chloride Substances 0.000 claims 1
- 235000011164 potassium chloride Nutrition 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 239000001632 sodium acetate Substances 0.000 claims 1
- 235000017281 sodium acetate Nutrition 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
- 239000000600 sorbitol Substances 0.000 claims 1
- 239000003381 stabilizer Substances 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 239000005720 sucrose Substances 0.000 claims 1
- 238000009210 therapy by ultrasound Methods 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024076371A JP7678625B2 (ja) | 2018-02-07 | 2024-05-09 | アルファポリグルタミン酸化ペメトレキセドおよびその使用 |
| JP2025072592A JP2025105820A (ja) | 2018-02-07 | 2025-04-24 | アルファポリグルタミン酸化ペメトレキセドおよびその使用 |
Applications Claiming Priority (17)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862627703P | 2018-02-07 | 2018-02-07 | |
| US201862627741P | 2018-02-07 | 2018-02-07 | |
| US62/627,741 | 2018-02-07 | ||
| US62/627,703 | 2018-02-07 | ||
| US201862630629P | 2018-02-14 | 2018-02-14 | |
| US62/630,629 | 2018-02-14 | ||
| US201862662374P | 2018-04-25 | 2018-04-25 | |
| US62/662,374 | 2018-04-25 | ||
| US201862702732P | 2018-07-24 | 2018-07-24 | |
| US201862702561P | 2018-07-24 | 2018-07-24 | |
| US62/702,732 | 2018-07-24 | ||
| US62/702,561 | 2018-07-24 | ||
| US201862764943P | 2018-08-17 | 2018-08-17 | |
| US201862764955P | 2018-08-17 | 2018-08-17 | |
| US62/764,955 | 2018-08-17 | ||
| US62/764,943 | 2018-08-17 | ||
| PCT/US2019/016989 WO2019157138A1 (en) | 2018-02-07 | 2019-02-07 | Alpha polyglutamated pemetrexed and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024076371A Division JP7678625B2 (ja) | 2018-02-07 | 2024-05-09 | アルファポリグルタミン酸化ペメトレキセドおよびその使用 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021512895A JP2021512895A (ja) | 2021-05-20 |
| JP2021512895A5 JP2021512895A5 (https=) | 2022-02-16 |
| JPWO2019157138A5 true JPWO2019157138A5 (https=) | 2022-02-16 |
| JP7491572B2 JP7491572B2 (ja) | 2024-05-28 |
Family
ID=67549083
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020542562A Active JP7491572B2 (ja) | 2018-02-07 | 2019-02-07 | アルファポリグルタミン酸化ペメトレキセドおよびその使用 |
| JP2024076371A Active JP7678625B2 (ja) | 2018-02-07 | 2024-05-09 | アルファポリグルタミン酸化ペメトレキセドおよびその使用 |
| JP2025072592A Pending JP2025105820A (ja) | 2018-02-07 | 2025-04-24 | アルファポリグルタミン酸化ペメトレキセドおよびその使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024076371A Active JP7678625B2 (ja) | 2018-02-07 | 2024-05-09 | アルファポリグルタミン酸化ペメトレキセドおよびその使用 |
| JP2025072592A Pending JP2025105820A (ja) | 2018-02-07 | 2025-04-24 | アルファポリグルタミン酸化ペメトレキセドおよびその使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US11779584B2 (https=) |
| EP (1) | EP3749317A4 (https=) |
| JP (3) | JP7491572B2 (https=) |
| CN (1) | CN111954531A (https=) |
| WO (1) | WO2019157138A1 (https=) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN120939250A (zh) | 2016-08-12 | 2025-11-14 | L.E.A.F.控股集团公司 | 聚谷氨酸化抗叶酸剂及其用途 |
| WO2018031968A1 (en) * | 2016-08-12 | 2018-02-15 | L.E.A.F. Holdings Group Llc | Alpha and gamma-d polyglutamated antifolates and uses thereof |
| EP3749319A4 (en) | 2018-02-07 | 2022-06-22 | L.E.A.F Holdings Group LLC | TETRAHYDROFOLATES ALPHA POLYGLUTAMATE AND THEIR USES |
| US12246015B2 (en) | 2018-02-07 | 2025-03-11 | L.E.A.F. Holdings Group Llc | Alpha polyglutamated raltitrexed and uses thereof |
| WO2019157123A1 (en) * | 2018-02-07 | 2019-08-15 | L.E.A.F. Holdings Group Llc | Alpha polyglutamated aminopterin and uses thereof |
| EP3749321A4 (en) * | 2018-02-07 | 2022-03-09 | L.E.A.F Holdings Group LLC | Gamma polyglutamated antifolates and uses thereof |
| WO2019157121A1 (en) | 2018-02-07 | 2019-08-15 | L.E.A.F. Holdings Group Llc | Alpha polyglutamated lometrexol and uses thereof |
| CA3090500A1 (en) * | 2018-02-07 | 2019-08-15 | L.E.A.F. Holdings Group Llc | Alpha polyglutamated antifolates and uses thereof |
| US12239734B2 (en) | 2018-02-07 | 2025-03-04 | L.E.A.F. Holdings Group Llc | Gamma polyglutamated raltitrexed and uses thereof |
| CN111954531A (zh) | 2018-02-07 | 2020-11-17 | L.E.A.F.控股集团公司 | α聚谷氨酸化培美曲塞及其用途 |
| US12220431B2 (en) | 2018-02-07 | 2025-02-11 | L.E.A.F. Holdings Group Llc | Gamma polyglutamated antifolates and uses thereof |
| EP3749311A4 (en) | 2018-02-07 | 2022-07-06 | L.E.A.F Holdings Group LLC | PEMETREXED POLYGLUTAMATE GAMMA COMPOSITIONS AND THEIR USES |
| WO2019157129A1 (en) | 2018-02-07 | 2019-08-15 | L.E.A.F. Holdings Group Llc | Alpha polyglutamated pralatrexate and uses thereof |
| JP7491573B2 (ja) | 2018-02-07 | 2024-05-28 | エル．イー．エー．エフ． ホールディングス グループ エルエルシー | アルファポリグルタミン酸化メトトレキセートおよびその使用 |
| EP3752157A4 (en) | 2018-02-14 | 2022-07-06 | L.E.A.F Holdings Group LLC | GAMMA-POLYGLUTAMATED LOMETREXOLE AND USES THEREOF |
| EP3752156A4 (en) | 2018-02-14 | 2021-10-27 | L.E.A.F Holdings Group LLC | GAMMA-POLYGLUTAMIZED PRALATREXATE AND USES THEREOF |
| CN111936145A (zh) | 2018-02-14 | 2020-11-13 | L.E.A.F.控股集团公司 | γ聚谷氨酸化氨甲蝶呤及其用途 |
| WO2019160732A1 (en) * | 2018-02-14 | 2019-08-22 | L.E.A.F. Holdings Group Llc | Gamma polyglutamated aminopterin and uses thereof |
| US12048766B2 (en) | 2018-02-14 | 2024-07-30 | L.E.A.F. Holdings Group Llc | Gamma polyglutamated tetrahydrofolates and uses thereof |
| KR102821508B1 (ko) | 2018-04-10 | 2025-06-16 | 셀렉타 바이오사이언시스, 인코퍼레이티드 | 인지질-플라베글린 접합체 및 표적화된 암 치료를 위해 이를 사용하는 방법 |
| CA3154192A1 (en) | 2019-10-10 | 2021-04-15 | Cellectar Biosciences, Inc. | Phospholipid-flavagline conjugates and methods of using the same for targeted cancer therapy |
| KR102557016B1 (ko) * | 2020-09-22 | 2023-07-20 | 비피진 주식회사 | 암 치료를 위한 cd47 바인더 및 리포좀 복합체 |
| KR102579284B1 (ko) * | 2020-09-22 | 2023-09-18 | 비피진 주식회사 | 신규의 cd47 바인더와 폴리뉴클레오티드를 포함하는 암 치료를 위한 리포좀 복합체 |
| CN114539353B (zh) * | 2020-11-26 | 2024-08-30 | 南京碳硅人工智能生物医药技术研究院有限公司 | 培美曲塞多谷氨酸化代谢物及其制备方法 |
| WO2022119531A1 (en) * | 2020-12-01 | 2022-06-09 | Ege Üni̇versi̇tesi̇ | Investigation of the potential of pemetrexed-loaded liposome system in cancer treatment |
Family Cites Families (130)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2564319A1 (fr) | 1984-05-21 | 1985-11-22 | Inst Nat Sante Rech Med | Nouvelles compositions de liposomes dotees d'une action specifique vis-a-vis de la proliferation de cellules donnees |
| US4584375A (en) | 1984-08-21 | 1986-04-22 | Rensselaer Polytechnic Institute | Fluorine-containing antifolates incapable of polyglutamate formation |
| KR0162654B1 (ko) | 1989-12-11 | 1998-11-16 | 알렌 제이. 시니스갤리 | N-(피롤로[2,3-d]피리미딘-3-일아크릴)-글루타민산 유도체 |
| EP0492316A1 (en) | 1990-12-14 | 1992-07-01 | Takeda Chemical Industries, Ltd. | Condensed heterocyclic oligoglutamate derivatives, their production and pharmaceutical compositions containing them |
| JP3202999B2 (ja) | 1991-01-31 | 2001-08-27 | 協和醗酵工業株式会社 | 肝移行性リポソーム製剤 |
| US5646253A (en) | 1994-03-08 | 1997-07-08 | Memorial Sloan-Kettering Cancer Center | Recombinant human anti-LK26 antibodies |
| US5416211A (en) | 1992-09-25 | 1995-05-16 | Eli Lilly And Company | Process for preparing 5-substituted pyrrolo-[2,3-d]pyrimidines |
| US6569432B1 (en) | 1995-02-24 | 2003-05-27 | Sloan-Kettering Institute For Cancer Research | Prostate-specific membrane antigen and uses thereof |
| US5795587A (en) | 1995-01-23 | 1998-08-18 | University Of Pittsburgh | Stable lipid-comprising drug delivery complexes and methods for their production |
| CN1122456C (zh) | 1996-01-31 | 2003-10-01 | 南亚拉巴马医学科学基金会 | 含有天然的还原叶酸盐异构体的食品和维生素制品 |
| US20020168761A1 (en) | 2000-01-24 | 2002-11-14 | Gour Barbara J. | Peptidomimetic modulators of cell adhesion |
| US20030073640A1 (en) | 1997-07-23 | 2003-04-17 | Ribozyme Pharmaceuticals, Inc. | Novel compositions for the delivery of negatively charged molecules |
| ZA987550B (en) | 1997-09-26 | 2000-02-21 | Lilly Co Eli | Processes and intermediates useful to make antifolates. |
| US6262262B1 (en) | 1997-09-26 | 2001-07-17 | Eli Lilly And Company | Processes and intermediates useful to make antifolates |
| US5912251A (en) | 1998-01-17 | 1999-06-15 | Nair; Madhavan G. | Metabolically inert anti-inflammatory and anti-tumor antifolates |
| US20050031679A1 (en) | 1998-03-27 | 2005-02-10 | Clemens Unger | Method for producing liposomal formulations of active ingredients |
| AU5283099A (en) | 1998-07-09 | 2000-02-01 | Rhodia Chimie | Water-soluble or water-dispersible grafted copolymers |
| US6066732A (en) | 1998-08-21 | 2000-05-23 | The Trustees Of Princeton University | Process for the preparation of pyrrolo[2,3-d]pyrimidines |
| US7244448B2 (en) | 2000-06-30 | 2007-07-17 | Tekmira Pharmaceuticals Corporation | Liposomal antineoplastic drugs and uses thereof |
| WO2001005405A1 (en) | 1999-07-16 | 2001-01-25 | The General Hospital Corporation | Folylpolyglutamyl synthetase gene transfer to enhance antifolate drug sensitivity |
| EP1212325A2 (en) | 1999-08-23 | 2002-06-12 | Eli Lilly And Company | A novel crystalline form of disodium n-[4-[2-(2-amino-4,7-dihydro-4-oxo-3h-pyrrolo[2,3-d]-pyrimidin-5-yl)ethyl]benzoyl]-l-glutamic acid salt and processes therefor |
| PT1259513E (pt) | 2000-02-25 | 2004-02-27 | Lilly Co Eli | Nova forma cristalina de acido n-¬4- ¬2-amino-4,7-dihidro -4-oxo-3h-pirrolo¬2,3-d|pirimidin-5-il)etil| - benzoil|-l-glutamico e processo para a sua obtencao |
| CN1095472C (zh) | 2000-04-17 | 2002-12-04 | 上海复康医药科技发展有限公司 | 叶酸－多聚糖复合物，其制备方法和以该复合物为活性成分的药物组合物 |
| AU7526901A (en) | 2000-06-09 | 2001-12-24 | Gilead Sciences Inc | Liposomal benzoquinazoline thymidylate synthase inhibitor formulations |
| EP1313508B1 (en) | 2000-06-30 | 2007-04-18 | Eli Lilly And Company | Combination containing an antifolate and methylmalonic acid lowering agent |
| US20050163832A1 (en) | 2002-02-13 | 2005-07-28 | Vladimir Torchilin | Intracellular delivery of therapeutic agents |
| CH696628A5 (de) | 2002-02-26 | 2007-08-31 | Eprova Ag | Verwendung von Folaten zur Herstellung einer Zubereitung geeignet zur Vorbeugung und Behandlung von Entzündungen und entzündungsassoziierter Krankheiten, im Speziellen zur Beeinflussung der |
| US7563590B2 (en) | 2002-08-30 | 2009-07-21 | Cypress Bioscience Inc. | Methods of quantifying methotrexate metabolites |
| US6921667B2 (en) | 2003-03-07 | 2005-07-26 | Prometheus Laboratories, Inc. | Methods for direct detection of individual methotrexate metabolites |
| US20040265368A1 (en) | 2003-04-02 | 2004-12-30 | Lawrence Mayer | Combination compositions of camptothecins and fluoropyrimidines |
| NZ548195A (en) | 2004-01-14 | 2011-01-28 | Gilead Sciences Inc | Lipid-based dispersions useful for drug delivery |
| CA2556027C (en) | 2004-02-12 | 2015-11-24 | Morphotek, Inc. | Monoclonal antibodies that specifically block biological activity of a tumor antigen |
| US7612071B2 (en) | 2004-03-12 | 2009-11-03 | Syntrix Biosystems, Inc. | Compositions and methods employing aminopterin |
| WO2005103250A1 (ja) | 2004-04-26 | 2005-11-03 | Takami Matsuyama | 葉酸リセプターベータ（FR-β）に対する単クローン抗体を含有する治療薬 |
| CA2928387A1 (en) | 2004-05-03 | 2005-11-17 | Merrimack Pharmaceuticals, Inc. | Drug delivery liposomes containing anionic polyols or anionic sugars |
| US7695908B2 (en) | 2004-06-15 | 2010-04-13 | Prometheus Laboratories Inc. | Methods for predicting methotrexate polyglutamate levels using pharmacogenetics |
| EP1791544A4 (en) | 2004-09-08 | 2007-09-12 | Chelsea Therapeutics Inc | CHINAZOLINE DERIVATIVES AS METABOLIC INERT ANTIFOLATE |
| WO2006035876A1 (ja) | 2004-09-29 | 2006-04-06 | Kowa Co., Ltd. | 関節リウマチの予防及び／又は治療薬 |
| US8126089B2 (en) | 2004-09-30 | 2012-02-28 | Alcatel Lucent | Method and apparatus for providing frame synchronization in a digital communication system that supports multiple modulation formats |
| US20100266709A1 (en) | 2004-12-16 | 2010-10-21 | Hicks Terry Lee | Compositions and Methods for Treating Burns |
| WO2006074416A1 (en) | 2005-01-07 | 2006-07-13 | Health Research Inc. | 5-amino-4-imidazolecarboxamide riboside and its nucleobase as potentiators of antifolate transport and metabolism |
| JP5042863B2 (ja) | 2005-02-14 | 2012-10-03 | サーナ・セラピューティクス・インコーポレイテッド | 生物学的に活性な分子をデリバリーするための脂質ナノ粒子系組成物および方法 |
| US7404969B2 (en) | 2005-02-14 | 2008-07-29 | Sirna Therapeutics, Inc. | Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules |
| JP2006248978A (ja) | 2005-03-10 | 2006-09-21 | Mebiopharm Co Ltd | 新規なリポソーム製剤 |
| GB2424837B (en) | 2005-04-06 | 2010-10-06 | Cilag Ag Int | Injection device |
| CA2619992A1 (en) * | 2005-08-24 | 2007-03-01 | Protherics Medicines Development Limited | Cleavage of antifolate compounds |
| US20090155345A1 (en) | 2005-12-08 | 2009-06-18 | Ben Gurion University Of The Negev Research And Development Authority | Methods for affecting liposome composition ultrasound irradiation |
| WO2007098089A2 (en) | 2006-02-17 | 2007-08-30 | Novacea, Inc. | Treatment of hyperproliferative diseases with methotrexate n-oxide and analogs |
| US9265746B2 (en) | 2006-05-31 | 2016-02-23 | Merck & Cie | Method for cell-specific targeting |
| EP1957497B1 (en) | 2006-08-14 | 2015-09-30 | Sicor, Inc. | Processes for preparing intermediates of pemetrexed |
| KR20090052355A (ko) | 2006-08-14 | 2009-05-25 | 시코르, 인크. | 순도가 높은 페메트렉세드 이산 및 이의 제조 방법 |
| WO2008030818A2 (en) | 2006-09-05 | 2008-03-13 | Mebiopharm Co., Ltd. | Novel liposome compositions |
| RU2423114C2 (ru) | 2006-12-29 | 2011-07-10 | Тракон Фармасьютикалз, Инк. | Комбинации антифолатного агента в лечении рака |
| KR101195366B1 (ko) | 2006-12-29 | 2012-11-21 | 트라콘 파마수티칼즈, 인코포레이티드 | 암치료에서의 항엽산제 조합물 |
| BRPI0806632A2 (pt) | 2007-01-19 | 2011-09-06 | Chelsea Therapeutics Inc | composto, composição farmacêutica, método para o tratamento de uma condição selecionada a partir do grupo constituìdo de proliferação celular anormal, inflamação, asma e artrite |
| US20100015218A1 (en) | 2007-02-16 | 2010-01-21 | Vasant Jadhav | Compositions and methods for potentiated activity of biologically active molecules |
| BRPI0807939A2 (pt) | 2007-04-03 | 2014-07-01 | Reddys Lab Ltd Dr | Formas sólidas de pemetrexed |
| CN101977620B (zh) | 2008-03-18 | 2014-05-07 | 英国技术集团国际有限公司 | 用于治疗类风湿性关节炎或急性骨髓性白血病的环戊二烯并[g]喹唑啉衍生物 |
| GB0811360D0 (en) | 2008-06-20 | 2008-07-30 | Imp Innovations Ltd | Methods |
| US20110224447A1 (en) | 2008-08-18 | 2011-09-15 | Bowman Keith A | Novel Lipid Nanoparticles and Novel Components for Delivery of Nucleic Acids |
| WO2010080724A1 (en) | 2009-01-12 | 2010-07-15 | Merck Sharp & Dohme Corp. | Novel lipid nanoparticles and novel components for delivery of nucleic acids |
| WO2010141711A1 (en) | 2009-06-03 | 2010-12-09 | Ex-Tek, Llc | Skin treatment compositions |
| US8569256B2 (en) | 2009-07-01 | 2013-10-29 | Protiva Biotherapeutics, Inc. | Cationic lipids and methods for the delivery of therapeutic agents |
| ES2613498T3 (es) | 2009-07-01 | 2017-05-24 | Protiva Biotherapeutics Inc. | Nuevas formulaciones de lípidos para el suministro de agentes terapéuticos a tumores sólidos |
| TW201118098A (en) | 2009-08-13 | 2011-06-01 | Reddy S Lab Liimited Dr | Processes for preparing pemetrexed |
| EP2467357B1 (en) | 2009-08-20 | 2016-03-30 | Sirna Therapeutics, Inc. | Novel cationic lipids with various head groups for oligonucleotide delivery |
| US20120253032A1 (en) | 2009-10-08 | 2012-10-04 | Merck Sharp & Dohme Corporation | Novel cationic lipids with short lipid chains for oligonucleotide delivery |
| US20130116419A1 (en) | 2010-01-22 | 2013-05-09 | Daniel Zewge | Post-synthetic chemical modification of rna at the 2'-position of the ribose ring via "click" chemistry |
| CN103037900B (zh) | 2010-02-24 | 2016-04-06 | 伊缪诺金公司 | 叶酸受体1抗体与免疫缀合物以及其用途 |
| JP5686886B2 (ja) | 2010-03-19 | 2015-03-18 | マサチューセッツ インスチテュート オブ テクノロジーＭａｓｓａｃｈｕｓｅｔｔｓ Ｉｎｓｔｉｔｕｔｅ Ｏｆ Ｔｅｃｈｎｏｌｏｇｙ | 脂質小胞組成物及び使用方法 |
| US9770414B2 (en) | 2010-05-13 | 2017-09-26 | Pacira Pharmaceuticals, Inc. | Sustained release formulation of methotrexate as a disease-modifying antirheumatic drug (DMARD) and an anti-cancer agent |
| EP2394640A1 (en) | 2010-05-21 | 2011-12-14 | MediGene AG | Improved liposomal formulations of lipophilic compounds |
| US8802863B2 (en) | 2010-05-24 | 2014-08-12 | Sirna Therapeutics, Inc. | Amino alcohol cationic lipids for oligonucleotide delivery |
| CA2800693A1 (en) | 2010-05-28 | 2011-12-01 | Purdue Research Foundation | Delivery of therapeutic agents to inflamed tissues using folate-targeted agents |
| US8748667B2 (en) | 2010-06-04 | 2014-06-10 | Sirna Therapeutics, Inc. | Low molecular weight cationic lipids for oligonucleotide delivery |
| IT1401677B1 (it) | 2010-07-22 | 2013-08-02 | Chemi Spa | Nuovo processo per la sintesi di pemetrexed sale disodico |
| CA2801523C (en) | 2010-07-30 | 2021-08-03 | Curevac Gmbh | Complexation of nucleic acids with disulfide-crosslinked cationic components for transfection and immunostimulation |
| WO2012033987A2 (en) | 2010-09-09 | 2012-03-15 | Purdue Research Foundation | Anti-human folate receptor beta antibodies and methods of use |
| WO2012037068A1 (en) | 2010-09-13 | 2012-03-22 | De Novo Diagnostics, Inc. | Methods for monitoring methotrexate therapy |
| ES2888231T3 (es) | 2010-09-20 | 2022-01-03 | Sirna Therapeutics Inc | Lípidos catiónicos de bajo peso molecular para el suministro de oligonucleótidos |
| EP2621480B1 (en) | 2010-09-30 | 2018-08-15 | Sirna Therapeutics, Inc. | Low molecular weight cationic lipids for oligonucleotide delivery |
| JP2013545727A (ja) | 2010-10-21 | 2013-12-26 | メルク・シャープ・アンド・ドーム・コーポレーション | オリゴヌクレオチド送達用の新規低分子量カチオン性脂質 |
| WO2012056285A1 (en) | 2010-10-25 | 2012-05-03 | Fresenius Kabi Oncology Ltd. | An improved process for the preparation of pemetrexed |
| WO2012061469A2 (en) | 2010-11-02 | 2012-05-10 | Sicor Inc. | Crystalline forms of pralatrexate |
| EP2635265B1 (en) | 2010-11-05 | 2018-04-04 | Sirna Therapeutics, Inc. | Novel low molecular weight cyclic amine containing cationic lipids for oligonucleotide delivery |
| AU2011323124C1 (en) | 2010-11-05 | 2016-09-22 | Eisai Inc. | Folate receptor alpha as a diagnostic and prognostic marker for folate receptor alpha-expressing cancers |
| WO2012078708A1 (en) | 2010-12-07 | 2012-06-14 | Chelsea Therapeutics, Inc. | Combination comprising methotrexate and an antifolate compound |
| US20140086939A1 (en) | 2011-02-28 | 2014-03-27 | Michael Karin | Compositions and methods for detecting and treating cancer |
| PL226015B1 (pl) * | 2011-03-03 | 2017-06-30 | Wrocławskie Centrum Badań Eit + Spółka Z Ograniczoną | Liposomowy preparat zawierajacy przeciwnowotworowa substancje aktywna, sposob jego wytwarzania i zawierajaca go kompozycja farmaceutyczna |
| WO2012121682A2 (en) | 2011-03-10 | 2012-09-13 | National Science And Technology Development Agency | Anti-folate antimalarials with dual-binding modes and their preparation |
| US8673914B2 (en) | 2011-03-28 | 2014-03-18 | St. John's University | Use of phosphodiesterase inhibitors for treating multidrug resistance |
| EP2508894A1 (en) | 2011-04-05 | 2012-10-10 | Receptomon LLC | Method for monitoring gene expression of translation and Integral/Secretory protein synthesis by magnetic resonance spectroscopy (MRS) |
| EP3354644A1 (en) | 2011-06-08 | 2018-08-01 | Translate Bio, Inc. | Cleavable lipids |
| US8183227B1 (en) | 2011-07-07 | 2012-05-22 | Chemo S. A. France | Compositions, kits and methods for nutrition supplementation |
| PT2731591T (pt) | 2011-07-13 | 2020-09-18 | Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd | Lipossomas que coencapsulam um bisfosfonato e um agente anfipático |
| PL2731972T3 (pl) | 2011-07-15 | 2018-06-29 | Eisai R&D Management Co., Ltd. | Przeciwciała skierowane przeciwko receptorowi folianowemu alfa i ich zastosowania |
| EP2591770B1 (en) | 2011-11-14 | 2016-03-16 | Silenseed Ltd | Compositions for siRNA delivery and methods of manufacturing and using same |
| US20150239956A1 (en) | 2012-06-27 | 2015-08-27 | Asahi Kasei Medical Co., Ltd. | High-affinity antibody and method for manufacturing the same |
| WO2014016740A2 (en) | 2012-07-23 | 2014-01-30 | Fresenius Kabi Oncology Ltd. | Improved process for the preparation of pralatrexate |
| ITRM20120398A1 (it) | 2012-08-08 | 2014-02-09 | Berlin Chemie Ag | Procedimento di sintesi pemetrexed e suo sale di lisina. |
| WO2014046630A1 (en) | 2012-09-19 | 2014-03-27 | Keskin, Dilek | Tumor targeted liposomal drug delivery system |
| US20140120157A1 (en) | 2012-09-19 | 2014-05-01 | Georgetown University | Targeted liposomes |
| JP6224619B2 (ja) | 2012-12-07 | 2017-11-01 | 協和発酵キリン株式会社 | 抗ｆｏｌｒ１抗体 |
| CN103040748B (zh) | 2012-12-18 | 2014-07-02 | 海南圣欣医药科技有限公司 | 一种培美曲塞二钠脂质体注射剂 |
| US9192609B2 (en) | 2013-04-17 | 2015-11-24 | Hedgepath Pharmaceuticals, Inc. | Treatment and prognostic monitoring of proliferation disorders using hedgehog pathway inhibitors |
| CA2911499A1 (en) | 2013-05-14 | 2014-11-20 | Immunogen, Inc. | Anti-folr1 immunoconjugate dosing regimens |
| MX386433B (es) * | 2014-08-14 | 2025-03-18 | L E A F Holdings Group Llc | Fármaco de afinidad encapsulado en liposoma. |
| JOP20170004B1 (ar) | 2016-01-15 | 2022-09-15 | Lilly Co Eli | الأجسام المضادة لببتيد بيتا النشوي مضاد N3pGlu واستخداماته |
| CN109069666B (zh) | 2016-04-29 | 2023-04-04 | 纪念斯隆凯特琳癌症中心 | 使靶向颗粒穿透、分布和响应于恶性脑肿瘤中的组合物和方法 |
| CN120939250A (zh) | 2016-08-12 | 2025-11-14 | L.E.A.F.控股集团公司 | 聚谷氨酸化抗叶酸剂及其用途 |
| WO2018031979A1 (en) * | 2016-08-12 | 2018-02-15 | L.E.A.F. Holdings Group Llc | Alpha and gamma-d polyglutamated antifolates and uses thereof |
| WO2018031968A1 (en) | 2016-08-12 | 2018-02-15 | L.E.A.F. Holdings Group Llc | Alpha and gamma-d polyglutamated antifolates and uses thereof |
| US20190231690A1 (en) | 2017-11-08 | 2019-08-01 | L.E.A.F. Holdings Group Llc | Platinum complexes and uses thereof |
| EP3749321A4 (en) | 2018-02-07 | 2022-03-09 | L.E.A.F Holdings Group LLC | Gamma polyglutamated antifolates and uses thereof |
| WO2019157121A1 (en) | 2018-02-07 | 2019-08-15 | L.E.A.F. Holdings Group Llc | Alpha polyglutamated lometrexol and uses thereof |
| CA3090500A1 (en) | 2018-02-07 | 2019-08-15 | L.E.A.F. Holdings Group Llc | Alpha polyglutamated antifolates and uses thereof |
| EP3749311A4 (en) | 2018-02-07 | 2022-07-06 | L.E.A.F Holdings Group LLC | PEMETREXED POLYGLUTAMATE GAMMA COMPOSITIONS AND THEIR USES |
| EP3749319A4 (en) | 2018-02-07 | 2022-06-22 | L.E.A.F Holdings Group LLC | TETRAHYDROFOLATES ALPHA POLYGLUTAMATE AND THEIR USES |
| WO2019157129A1 (en) | 2018-02-07 | 2019-08-15 | L.E.A.F. Holdings Group Llc | Alpha polyglutamated pralatrexate and uses thereof |
| JP7491573B2 (ja) | 2018-02-07 | 2024-05-28 | エル．イー．エー．エフ． ホールディングス グループ エルエルシー | アルファポリグルタミン酸化メトトレキセートおよびその使用 |
| US12239734B2 (en) | 2018-02-07 | 2025-03-04 | L.E.A.F. Holdings Group Llc | Gamma polyglutamated raltitrexed and uses thereof |
| US12246015B2 (en) | 2018-02-07 | 2025-03-11 | L.E.A.F. Holdings Group Llc | Alpha polyglutamated raltitrexed and uses thereof |
| CN111954531A (zh) | 2018-02-07 | 2020-11-17 | L.E.A.F.控股集团公司 | α聚谷氨酸化培美曲塞及其用途 |
| WO2019157123A1 (en) | 2018-02-07 | 2019-08-15 | L.E.A.F. Holdings Group Llc | Alpha polyglutamated aminopterin and uses thereof |
| EP3752157A4 (en) | 2018-02-14 | 2022-07-06 | L.E.A.F Holdings Group LLC | GAMMA-POLYGLUTAMATED LOMETREXOLE AND USES THEREOF |
| WO2019160732A1 (en) | 2018-02-14 | 2019-08-22 | L.E.A.F. Holdings Group Llc | Gamma polyglutamated aminopterin and uses thereof |
| CN111936145A (zh) | 2018-02-14 | 2020-11-13 | L.E.A.F.控股集团公司 | γ聚谷氨酸化氨甲蝶呤及其用途 |
| EP3752156A4 (en) | 2018-02-14 | 2021-10-27 | L.E.A.F Holdings Group LLC | GAMMA-POLYGLUTAMIZED PRALATREXATE AND USES THEREOF |
| US12048766B2 (en) | 2018-02-14 | 2024-07-30 | L.E.A.F. Holdings Group Llc | Gamma polyglutamated tetrahydrofolates and uses thereof |
| CA3149914A1 (en) | 2019-08-06 | 2021-02-11 | L.E.A.F. Holdings Group Llc | Processes of preparing polyglutamated antifolates and uses of their compositions |
-
2019
- 2019-02-07 CN CN201980024908.7A patent/CN111954531A/zh active Pending
- 2019-02-07 WO PCT/US2019/016989 patent/WO2019157138A1/en not_active Ceased
- 2019-02-07 JP JP2020542562A patent/JP7491572B2/ja active Active
- 2019-02-07 EP EP19751234.6A patent/EP3749317A4/en active Pending
- 2019-02-07 US US16/967,212 patent/US11779584B2/en active Active
-
2023
- 2023-06-01 US US18/204,566 patent/US12433893B2/en active Active
-
2024
- 2024-05-09 JP JP2024076371A patent/JP7678625B2/ja active Active
-
2025
- 2025-04-24 JP JP2025072592A patent/JP2025105820A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021512895A5 (https=) | ||
| JP2021513528A5 (https=) | ||
| JPWO2019157138A5 (https=) | ||
| JP2021514357A5 (https=) | ||
| JP2021513531A5 (https=) | ||
| JP2021513525A5 (https=) | ||
| JP2021513550A5 (https=) | ||
| JPWO2019157145A5 (https=) | ||
| JP2021513529A5 (https=) | ||
| JPWO2019157125A5 (https=) | ||
| JPWO2019157120A5 (https=) | ||
| JPWO2019160733A5 (https=) | ||
| JP2021513533A5 (https=) | ||
| JP2019524885A5 (https=) | ||
| JP2017526744A5 (https=) | ||
| JPWO2019160735A5 (https=) | ||
| JPWO2019157146A5 (https=) | ||
| Suk et al. | Lung gene therapy with highly compacted DNA nanoparticles that overcome the mucus barrier | |
| Wu et al. | Reversing of multidrug resistance breast cancer by co-delivery of P-gp siRNA and doxorubicin via folic acid-modified core-shell nanomicelles | |
| Paukner et al. | Bacterial ghosts as novel advanced drug delivery systems: antiproliferative activity of loaded doxorubicin in human Caco-2 cells | |
| Joo et al. | Crosslinked multilamellar liposomes for controlled delivery of anticancer drugs | |
| JP2025072362A5 (https=) | ||
| JPWO2019157148A5 (https=) | ||
| BR112020022077A2 (pt) | composições de carotenoides e seus usos | |
| Chatzikleanthous et al. | Design of a novel vaccine nanotechnology-based delivery system comprising CpGODN-protein conjugate anchored to liposomes |